EXPLANATORY NOTE
On August 9, 2022, Disc Medicine, Inc. (formerly known as Gemini Therapeutics, Inc.) (the Registrant) entered into an Agreement
and Plan of Merger (the Merger Agreement) with Disc Medicine Opco, Inc. (formerly known as Disc Medicine, Inc.) (Disc) and Gemstone Merger Sub, Inc., a wholly-owned subsidiary of the Registrant
(Merger Sub), whereby Merger Sub merged with and into Disc, with Disc surviving such merger as a wholly-owned subsidiary of the Registrant (the Merger). Upon the closing of the Merger, Gemini
Therapeutics, Inc. was renamed Disc Medicine, Inc.
On December 28, 2022, at a special meeting of the stockholders, the stockholders of the
Registrant approved a 1-for-10 reverse stock split of the Registrants Common Stock (as defined below) (the Reverse Stock Split) an
increase to the number of shares reserved for issuance under the 2021 Plan of 1,338,879 shares of Common Stock, and an increase to the number of shares reserved for issuance under the 2021 ESPP of 137,839 shares of Common Stock.
Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the Effective Time), each option to purchase
Disc common stock that was outstanding and unexercised immediately prior to the Effective Time under the Disc 2017 Plan, whether or not vested, automatically converted into and became an option to purchase Common Stock of the Registrant, and the
Registrant assumed the Disc 2017 Plan and each such Disc option in accordance with the terms of the Disc 2017 Plan and the terms of each stock option agreement by which such Disc option is evidenced.
The number of shares of Common Stock reserved and available for issuance under the 2021 Plan is subject to an automatic annual increase on each
January 1, beginning in 2022, by an amount equal to the lesser of: (i) four percent (4%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or (ii) such lesser number of shares
of Common Stock as determined by the Registrants board of directors or the compensation committee of the Registrants board of directors. Accordingly, on January 1, 2023, the number of shares of Common Stock reserved and available
for issuance under the 2021 Plan increased by 696,224 shares.
The number of shares of Common Stock reserved and available for issuance under the 2021
ESPP is subject to an automatic increase on January 1, 2023 and each January 1 thereafter through January 1, 2031, by the least of (i) 1% of the outstanding number of shares of Common Stock on the immediately preceding
December 31, (ii) 43,055 shares of Common Stock, or (iii) such number of shares of Common Stock as determined by the administrator of the 2021 ESPP. Accordingly, on January 1, 2023, the number of shares of Common Stock
reserved and available for issuance under the 2021 ESPP increased by 43,055 shares.
This Registration Statement registers (i) 1,672,599 shares of common
stock of the Registrant, par value $0.0001 per share (the Common Stock), issuable with respect to Disc options assumed by the Registrant pursuant to the Merger Agreement, (ii) 2,035,103 additional shares of Common
Stock reserved and available for future issuance under the 2021 Plan and (iii) 180,894 additional shares of Common Stock reserved and available for future issuance under the 2021 ESPP. All applicable share amounts reflect the Reverse Stock
Split.
The additional shares reserved and available for future issuance under the 2021 Plan and 2021 ESPP are of the same class as other securities
relating to the 2021 Plan and 2021 ESPP for which the Registrants Registration Statements filed on Form
S-8 filed with the Securities and Exchange Commission on April 13, 2021 (File
No. 333-255194), October 14, 2021 (File No. 333-260243) and
March 10, 2022 (File No. 333-263410), are effective. The information contained in the Registrants
Registration Statements on Form S-8 (Registration No. 333-255194, 333-260243 and
333-263410) is hereby incorporated by reference pursuant to General Instruction E.